News and Trends 3 Oct 2022Poxel granted orphan drug designation for kidney disease treatment French biopharma company Poxel SA says the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to… October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jul 2021Poxel’s Diabetes Drug Wins Japan Nod, But Competition Remains Fierce As French biotech Poxel marks the first market approval of its oral type 2 diabetes medication in Japan, eyes turn… July 2, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Jul 2019The Top 10 Biotechs You’ll Find in Lyon Lyon is one of the hotspots for biotech in Europe. Here are 10 of the most successful biotech companies in… July 10, 2019 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Apr 2019French First-in-Class Diabetes Drug Nails Phase III Trial An oral first-in-class drug targeting the mitochondria, developed by the French biotech Poxel, has shown big potential for treating type… April 9, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2018French Biotech Takes its Oral Diabetes Drug to Phase III Update (13/03/2018): Poxel has started two more Phase III trials in Japan testing its drug for type 2 diabetes, imeglimin.… March 13, 2018 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 12 Feb 2018Healthcare-Biotech Partnership Pledges to Take its Type 2 Diabetes Treatment Worldwide Swiss pharma Roivant has given French biotech Poxel €28M upfront to get involved with the development and commercialization of imeglimin, a… February 12, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016Stories We Didn’t Cover: Next Human CRISPR Trials by Intellia? Try as we might, we can't cover all the biotech news out there. During the week, we only pick the… December 9, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2016Poxel raises €26.5M to support Phase III trial in Diabetes Poxel has closed a capital increase on the Euronext Paris, raising €26.5M. The money is intended to fund its plans… July 19, 2016 - 2 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 29 May 2015Poxel is Looking towards Japan’s Lucrative Diabetes Market Poxel, the French company that made a €27M IPO last February, announced the successful conclusion of a phase 1 clinical… May 29, 2015 - 2 minutesmins - By Joachim Eeckhout Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2015After its IPO, Poxel maintains its promise to develop a new Type 2 diabetes drug Poxel continues to interest the market after its successful IPO in February 2015, where it has raised approximately €27M with… May 3, 2015 - 3 minutesmins - By Joachim Eeckhout Share WhatsApp Twitter Linkedin Email